Circulating microRNAs as candidate markers to distinguish heart failure in breathless patients
暂无分享,去创建一个
V. Cameron | C. Frampton | A. Richards | R. Troughton | Richard W Troughton | A Mark Richards | Chris M Frampton | Vicky A Cameron | K. Ellis | L. Ellmers | Katrina L Ellis | Leigh J Ellmers | A. Richards | Leigh. J. Ellmers
[1] S. Manzano-Fernández,et al. Highly sensitive troponin T for risk stratification of acutely destabilized heart failure. , 2012, American heart journal.
[2] A. Tijsen,et al. Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease? , 2012, Circulation research.
[3] Offer Amir,et al. Serum levels of microRNAs in patients with heart failure , 2012, European journal of heart failure.
[4] J. Bauersachs,et al. Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome. , 2011, Journal of molecular and cellular cardiology.
[5] Min Liu,et al. MicroRNA‐142‐3p, a new regulator of RAC1, suppresses the migration and invasion of hepatocellular carcinoma cells , 2011, FEBS letters.
[6] Y. Liu,et al. MicroRNA expression signature in atrial fibrillation with mitral stenosis. , 2011, Physiological genomics.
[7] H. Nonogi,et al. Assessment of plasma miRNAs in congestive heart failure. , 2011, Circulation journal : official journal of the Japanese Circulation Society.
[8] Jan A Staessen,et al. Circulating MicroRNA-208b and MicroRNA-499 Reflect Myocardial Damage in Cardiovascular Disease , 2010, Circulation. Cardiovascular genetics.
[9] Christopher M O'Connor,et al. Troponin elevation in heart failure prevalence, mechanisms, and clinical implications. , 2010, Journal of the American College of Cardiology.
[10] F. Crea,et al. MicroRNA signatures in peripheral blood mononuclear cells of chronic heart failure patients. , 2010, Physiological genomics.
[11] Kunihiro Nishimura,et al. Plasma microRNA 499 as a biomarker of acute myocardial infarction. , 2010, Clinical chemistry.
[12] Federica Limana,et al. Circulating microRNAs are new and sensitive biomarkers of myocardial infarction , 2010, European heart journal.
[13] Perry D Moerland,et al. MiR423-5p As a Circulating Biomarker for Heart Failure , 2010, Circulation research.
[14] N. Sawada,et al. Novel aspects of the roles of Rac1 GTPase in the cardiovascular system. , 2010, Current opinion in pharmacology.
[15] R. Jaenisch,et al. Loss of Cardiac microRNA-Mediated Regulation Leads to Dilated Cardiomyopathy and Heart Failure , 2009, Circulation research.
[16] Jianqin Jiao,et al. miR-23a functions downstream of NFATc3 to regulate cardiac hypertrophy , 2009, Proceedings of the National Academy of Sciences.
[17] Frank Speleman,et al. A novel and universal method for microRNA RT-qPCR data normalization , 2009, Genome Biology.
[18] S. Vatner,et al. Downregulation of MiR-199a Derepresses Hypoxia-Inducible Factor-1α and Sirtuin 1 and Recapitulates Hypoxia Preconditioning in Cardiac Myocytes , 2009, Circulation research.
[19] Derek J Van Booven,et al. Reciprocal Regulation of Myocardial microRNAs and Messenger RNA in Human Cardiomyopathy and Reversal of the microRNA Signature by Biomechanical Support , 2009, Circulation.
[20] Susan Anderson,et al. Irbesartan in patients with heart failure and preserved ejection fraction. , 2008, The New England journal of medicine.
[21] I. Bozzoni,et al. Concerted microRNA control of Hedgehog signalling in cerebellar neuronal progenitor and tumour cells , 2008, The EMBO journal.
[22] M. Washington,et al. Epigenetic silencing of the intronic microRNA hsa-miR-342 and its host gene EVL in colorectal cancer , 2008, Oncogene.
[23] Sek Won Kong,et al. Altered microRNA expression in human heart disease. , 2007, Physiological genomics.
[24] Peter T Nelson,et al. Energizing miRNA research: a review of the role of miRNAs in lipid metabolism, with a prediction that miR-103/107 regulates human metabolic pathways. , 2007, Molecular genetics and metabolism.
[25] Thomas Thum,et al. MicroRNAs in the Human Heart: A Clue to Fetal Gene Reprogramming in Heart Failure , 2007, Circulation.
[26] George A. Calin,et al. A MicroRNA Signature of Hypoxia , 2006, Molecular and Cellular Biology.
[27] M. Peppelenbosch,et al. Hedgehog morphogen in cardiovascular disease. , 2006, Circulation.
[28] V. Roger,et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. , 2006, The New England journal of medicine.
[29] D. Bartel. MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.
[30] Karl Swedberg,et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial , 2003, The Lancet.
[31] Daniel Levy,et al. Long-term trends in the incidence of and survival with heart failure. , 2002, The New England journal of medicine.
[32] F. Speleman,et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes , 2002, Genome Biology.
[33] Y. Yazaki,et al. The role of the natriuretic peptides in the cardiovascular system. , 2001, Cardiovascular research.
[34] C. Frampton,et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. , 1998, Circulation.
[35] R. Doughty,et al. Immunoreactive amino‐terminal pro‐brain natriuretic peptide (NT‐PROBNP): a new marker of cardiac impairment , 1997, Clinical endocrinology.
[36] A. Richards,et al. Plasma brain natriuretic peptide in assessment of acute dyspnoea , 1994, The Lancet.
[37] N. Reichek,et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. , 1989, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.